Alkem Laboratories Limited — Important, 13-11-2024: Financial Result Updates

Alkem Laboratories Ltd. reported its latest consolidated financial results for the quarter and half-year ended September 30, 2024.

Total revenue from operations reached ₹34,147 million for Q2FY25, reflecting a slight decline of 0.7% year-over-year (YoY), whereas half-year revenue was ₹64,465 million, reflecting a 0.6% increase YoY. The revenue growth was primarily driven by a 5.7% increase in domestic sales, which totaled ₹24,610 million in Q2FY25, while international sales, at ₹9,181 million, decreased by 12.9%.

Net profit for the quarter was ₹6,886 million, demonstrating an 11.0% increase YoY. The earnings before interest, tax, depreciation, and amortization (EBITDA) for the quarter amounted to ₹7,528 million, supported by a margin improvement to 22.0% from 21.7%.

Operational costs increased modestly, with total expenses rising to ₹27,689 million in Q2, particularly driven by staff-related expenses and material costs. The balance sheet shows healthy growth in total assets amounting to ₹171,170 million as at September 30, 2024, with significant cash and equivalents of approximately ₹4,126 million demonstrating solid liquidity.

Given the consistent growth in domestic sales and strategic cost management efforts, Alkem's outlook remains optimistic. The company's solid market positioning, particularly in high-demand therapeutic areas, suggests continued growth potential. This performance supports a cautiously positive stance among investors.